Comparison of Evolut FX Versus Sapien 3 Ultra Resilia.
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Christian Juhl Terkelsen
- Trial code
- NCT06470022
- Record updated
- 25 August 2026
- Original description
To compare outcome in patients randomized to treatment with Evolut FX versus Sapien 3 Ultra Resilia.Read full original descriptionShow less
Randomized Comparison of Evolut FX Versus Sapien 3 Ultra Resilia. The Compare-TAVI 2 Trial
To compare outcome in patients randomized to treatment with Evolut FX versus Sapien 3 Ultra Resilia.
Inclusion: Patient more than 18 years of age; Patient eligible for both Evolut FX and Edwards Sapien 3 Ultra Resilia according to a TAVI heart team conference; The center experience for each of the valves considered should be more than 15 cases a year, and the treating physician should have implanted at least 15 of each valve used in the trial; The center volume should be more than 75 cases a year; The patient has given signed informed consent; TAVI performed via the femoral artery.
Exclusion: None.